Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Actionable mutational profiling in solid tumors using hybrid-capture-based next-generation sequencing in a real-world setting in Spain.
Zazo S, Pérez-Buira S, Carvajal N, Plaza-Sánchez J, Manso R, Pérez-González N, Dominguez C, Prieto-Potin I, Rubio J, Dómine M, Lozano V, Mohedano P, Carcedo D, Carias R, Rojo F. Zazo S, et al. Among authors: carcedo d. Cancer Med. 2024 Feb;13(3):e6827. doi: 10.1002/cam4.6827. Epub 2024 Jan 11. Cancer Med. 2024. PMID: 38213074 Free PMC article.
Cost-effectiveness of adjuvant atezolizumab versus best supportive care in the treatment of patients with resectable early-stage non-small cell lung cancer and overexpression of PD-L1.
Escudero-Vilaplana V, Collado-Borrell R, De Castro J, Insa A, Martínez A, Fernández E, Sullivan I, Flores A, Arrabal N, Carcedo D, Manzaneque A. Escudero-Vilaplana V, et al. Among authors: carcedo d. J Med Econ. 2023 Jan-Dec;26(1):445-453. doi: 10.1080/13696998.2023.2188844. J Med Econ. 2023. PMID: 36883193 Free article.
Cost-Effectiveness of Next-Generation Sequencing Versus Single-Gene Testing for the Molecular Diagnosis of Patients With Metastatic Non-Small-Cell Lung Cancer From the Perspective of Spanish Reference Centers.
Arriola E, Bernabé R, Campelo RG, Biscuola M, Enguita AB, López-Ríos F, Martínez R, Mezquita L, Palanca S, Pareja MJ, Zugazagoitia J, Arrabal N, García JF, Carcedo D, de Álava E. Arriola E, et al. Among authors: carcedo d. JCO Precis Oncol. 2023 Mar;7:e2200546. doi: 10.1200/PO.22.00546. JCO Precis Oncol. 2023. PMID: 36862967 Free PMC article.
Cost-Effectiveness of the CNIC-Polypill Strategy Compared With Separate Monocomponents in Secondary Prevention of Cardiovascular and Cerebrovascular Disease in Portugal: The MERCURY Study.
Aguiar C, Araujo F, Rubio-Mercade G, Carcedo D, Paz S, Castellano JM, Fuster V. Aguiar C, et al. Among authors: carcedo d. J Health Econ Outcomes Res. 2022 Nov 22;9(2):134-146. doi: 10.36469/001c.39768. eCollection 2022. J Health Econ Outcomes Res. 2022. PMID: 36475278 Free PMC article.
Cost-effectiveness analysis of molecular diagnosis by next-generation sequencing versus sequential single testing in metastatic non-small cell lung cancer patients from a south Spanish hospital perspective.
de Alava E, Pareja MJ, Carcedo D, Arrabal N, García JF, Bernabé-Caro R. de Alava E, et al. Among authors: carcedo d. Expert Rev Pharmacoecon Outcomes Res. 2022 Sep;22(6):1033-1042. doi: 10.1080/14737167.2022.2078310. Epub 2022 May 25. Expert Rev Pharmacoecon Outcomes Res. 2022. PMID: 35593180 Free article.
Biomarker testing strategies in non-small cell lung cancer in the real-world setting: analysis of methods in the Prospective Central Lung Cancer Biomarker Registry (LungPath) from the Spanish Society of Pathology (SEAP).
Martín-López J, Rojo F, Martínez-Pozo A, Hernández-Iglesias T, Carcedo D, de Alda LR, García JF, Salas C. Martín-López J, et al. Among authors: carcedo d. J Clin Pathol. 2023 May;76(5):327-332. doi: 10.1136/jclinpath-2021-208034. Epub 2021 Dec 13. J Clin Pathol. 2023. PMID: 34903610 Free PMC article.
17 results